Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JY05 is a biosimilar candidate of dulaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Hangzhou Jiuyuan Genetic Biopharmaceutical (also known as Hangzhou Yuanda Biopharmaceutical), JY05 is a recombinant fusion protein consisting of two GLP-1 molecules linked to a human IgG4 Fc fragment. The drug acts by binding to and activating the GLP-1 receptor, which enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying. It is primarily being developed for the treatment of type 2 diabetes and is currently in Phase 1 clinical trials to demonstrate bioequivalence and safety compared to the reference product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JY05.